SCHEMBL14729099

SCHEMBL14729099

CS(=O)(=O)c1ccc(-c2ccc3nc(OC4CCN(C(=O)c5ccccc5)CC4)sc3c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIPC P11150 5/20 0.45
HPGD P15428 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
MAPT P10636 2/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
LIPG Q9Y5X9 5/20 0.42
P2RX7 Q99572 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HRH1 P35367 2/20 0.42
CCR3 P51677 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591259 0.90 GPR119 (0.43) GPR119ALDH1A1LMNA
SCHEMBL14729100 0.88 IKBKB (0.44) LIPCGPR119ALDH1A1LMNA
SCHEMBL14729093 0.87 GPR119 (0.47) LIPCGPR119LIPGALDH1A1LMNA
SCHEMBL14729101 0.86 LIPG (0.45) NPC1RAB9AGPR119LIPGMEN1
SCHEMBL14729097 0.86 MAPT (0.45) GPR119MAPTALDH1A1LMNA
SCHEMBL14729195 0.85 GPR119 (0.41) GPR119ALDH1A1LMNA
SCHEMBL2583595 0.84 GPR119 (0.58) GPR119
SCHEMBL14729197 0.83 GPR119 (0.41) LIPCGPR119LIPGMEN1ALDH1A1
SCHEMBL14729201 0.83 CLK1 (0.41) GPR119ALDH1A1LMNA
SCHEMBL14729095 0.83 GPR119 (0.48) HPGDGPR119ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
US-8940716-B2 Bicyclic heteroaryl compounds as GPR119 modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-27 US disclosed
EP-2566860-B1 BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS BRISTOL MYERS SQUIBB CO (US) 2014-09-10 EP disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053345-A1 BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS GPR119, GPR139, GPR4 LIPC 1982/4885HPGD 1972/4885NPC1 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.